was used. Forty-five patients were men and 38 were women. The median age was 54 years (range, 25-90 years). All patients had a KPS score of greater than or equal to 40 (median KPS score of 70, range 40-90). Histological types were classified as radioresponsive and radioresistant, and based on previous conventional fractionated radiotherapy results, 66% of the tumors were considered radioresponsive. These tumors included lung carcinoma (33 cases), unknown primary carcinoma (three cases), gynecological cancer (five cases), breast cancer (seven cases), adenocarcinoma of the gastrointestinal tract (five cases), and others (one testicular germ cell tumor and one bronchial carcinoid). The other 34% of the tumors were considered to be radioresistant and included malignant melanoma, renal cell carcinoma, and sarcoma in 19, six, and three cases, respectively. In 26 patients (31%) stable extracranial disease was demonstrated, and in 57 patients (69%) uncontrolled primary disease and/or disseminated systemic disease at the time of SRS was demonstrated. Approximately half of the metastases were located supratentorially (53%), 7% were located infratentorially, and 40% were located on both sides of the tentorium. The median number of metastases was two per patient (range 2-7 lesions), and the median diameter of metastatic lesions was 25 mm (range 7-60 mm). Of the 83 patients, forty-four patients (53%) harbored two metastases, 22 (27%) three metastases, and 17 (20%) four or more lesions in the brain. Patient characteristics are summarized in Table 1 .
Thirty-eight patients were treated with SRS as a salvage therapy for recurrent (or persistent) disease following previous WBRT, and 45 patients underwent SRS as a primary treatment for newly diagnosed brain metastases: 36 patients received WBRT in conjunction with SRS, eight patients underwent SRS alone without WBRT because of concerns expressed by the patient and/or radioresistant tumor type, and one remaining patient with small cell lung cancer in whom prophylactic cranial radiotherapy was performed prior to SRS underwent SRS alone. Nineteen patients had previously undergone tumor resection. Treatment is summarized in Table 2 . Our decision to combine these two groups of patients with different tumor status (that is, recurrent and newly diagnosed) to increase the sample size for our analysis was based on our finding that overall survival length between the two groups was comparable. Analysis of other studies also indicates comparable outcomes between patients with recurrent disease and those with newly diagnosed disease.
1,13,18

Treatment Technique
The Brown-Roberts-Wells stereotactic frame (Radionics, Inc., Burlington, MA) was applied after induction of local anesthesia for head fixation during CT scanning and at the time of treatment. Scans of the head were obtained in 4-mm sections outside the tumor volume and with either 1-or 2-mm sections through the lesion. Treatment planning for the first 37 patients was performed using an SRS system (Philips SRS 200 Stereotactic Radiosurgery System; Philips Medical Systems, London, United Kingdom); and the remaining 46 were treated using a different system (X-Knife Stereotactic Radiosurgery System; Radionics Software Applications, Inc., Burlington, MA).
The target and dose-limiting structures, such as the eyes, optic nerves, optic chiasm, and brainstem, were delineated on CT scanning. The target was defined as a contrast-enhancing tumor demonstrated on CT scans.
Treatment planning to determine the treatment isodose, maximum dose, and dose to the enhancing margin of the tumor was performed by the radiation oncologist, neurosurgeon, and radiation physicist. The number of isocenters, collimator sizes, and number of arcs and degrees of gantry rotation were chosen to optimize the radiation dose to the target and to minimize the dose to the adjacent normal brain parenchyma. The MPD encompassing the target was chosen to prescribe the dose to the target. This prescription dose was normalized to the maximum dose within the treatment volume. A wide range of MPDs (range 6-50 Gy) was used depending on the size of tumor (diameter range 0.8-5.5). However, the majority of patients (76 [92%] of 83 patients) were treated with doses between 10 Gy and 20 Gy, with a median MPD of 15 Gy prescribed to the 40 to 90% (median 87%) IDS encompassing the target. All patients were treated with a single fraction. The planning system included algorithms to calculate the treatment volume, to which the chosen MPD was delivered to encompass completely the enhancing tumor. Consequent- ly, the treatment volume was defined as the tissue volume within the IDS to which the MPD was prescribed. After treatment, patients underwent serial neurological and radiological examinations. Routine follow-up CT or magnetic resonance images were obtained every 2 to 3 months or if neurological functioning worsened unexpectedly. These neuroimages were reviewed by the members of the radiosurgical team to assess the therapeutic response. Patients who lived at a distance from Minneapolis were monitored by telephone with the assistance of the patient's primary physician or oncologist.
Statistical Analysis
Actuarial LPFS, regional progression-free survival (RPFS), and overall survival were calculated from the date of treatment by using the Kaplan-Meier method. The event for survival computation was defined as local progression for LPFS, regional progression for RPFS, and the death of patients, for overall survival. A local progression was defined as contiguous enlargement of contrast enhancement observed beyond the treatment volume on neuroimages. Regional progression was defined as noncontiguous recurrence of the tumor observed outside the treatment volume, which included new parenchymal brain metastases or leptomeningeal carcinomatosis. Univariate comparisons of survival between different groups were performed using the log-rank test. Variables that were compared included sex (male compared with female) KPS score (Ͻ 70 compared with ≥ 70), histological tumor type (radioresponsive compared with radioresistant), tumor status (recurrent compared with newly diagnosed), extracranial disease (absent compared with present), location of metastases (one side compared with both sides of tentorium), number of metastases (two, three, or greater than or equal to four), previous tumor resection (yes compared with no), and treatment modality (SRS only compared with combined SRS/WBRT). To understand the causes of death, two types of disease-specific survival were analyzed: neurological-specific survival and extracranial-specific survival. For neurological-specific survival, only deaths due to progressive disease in the brain were scored as events; death due to progression of extracranial (systemic or intercurrent) disease were censored at the time of death. Likewise, extracranial-specific deaths due to extracranial progression were scored as events; death due to neurological progression were censored at the time of death.
RESULTS
Patterns of Failure and LPFS and RPFS
Patients who died within 3 months of radiosurgery or who were followed for fewer than 3 months were excluded from evaluation of patterns of failure to halt progression of disease. Based on these criteria, 62 patients were eligible for evaluation. In nine (15%) of these 62 patients local progression was demonstrated at 3 to 9 months after the time of radiosurgery ( Table 3 ). The rate of LPFS was 81% at both 1 and 2 years postsurgery (Fig. 1) . Regional progression of disease was a more common pattern of failure than local progression after SRS and was observed in 24 (39%) of 62 patients: 20 patients developed new parenchymal metastatic lesion(s) and four patients developed leptomeningeal carcinomatosis (Table 3 ). The rate of RPFS was 48% at 1 year and 18% at 2 years (Fig. 1 ).
Survival Length
All 83 patients were included in the analysis of overall survival. Actuarial survival rates were 22% at 1 year and 13% at 2 years, with a median survival length of 5.4 months (range 0.3-28.8 months) from the time of SRS (Fig. 1) . At the time of analysis, 22 patients (27%) were alive at a range of 0.3 to 24.6 months after the time of treatment.
Univariate comparisons of survival lengths between groups, tested by the log-rank test, are summarized in Table 4. Variables that predicted longer survival, based on a log-rank test, were a KPS score greater than or equal to 70, the absence of extracranial disease, and fewer number of metastases. Figure 2 shows actuarial survival curves for these variables. Survival time following SRS was not sig-
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Twenty-five patients (30%) died of progressive disease within the central nervous system (neurological-related death) and the remaining 36 patients (43%) died of progressive extracranial (systemic or intercurrent) disease. Of the 36 patients who died of extracranial disease, 29 died of extracranial progression of the cancer and seven died of intercurrent disease. Figure 3 shows the neurological-specific survival and extracranial-specific survival rates. Actuarial neurological-specific survival rates were 47% at 1 year and 33% at 2 years, with a median of 12 months from the time of SRS; actuarial extracranial-specific survival rates were 45% at 1 year and 40% at 2 years, with a median of 9.8 months (Fig. 3) .
Treatment-Related Complications
The perioperative morbidity was minimal, and no radiosurgical treatment-related death was observed. No major bleeding or infection was observed at the insertion sites where the scalp pins were attached to the skull. Anticonvulsant medications were not routinely prescribed unless the patient had a history of seizures or harbored a cortical lesion. One patient with no history of seizures experienced a generalized seizure during the placement of the head frame and received anticonvulsant medication after the seizure. Patients did not routinely receive corticosteroid agents unless they had significant vasogenic * As determined by log-rank test. † Thirty-nine patients who had received WBRT prior to SRS (38 patients with recurrent/persistent brain metastases following WBRT and one patient with small cell lung cancer treated with prophylactic cranial radiotherapy) were included in the group of SRS alone because WBRT was not administered in conjunction with SRS. The remaining eight patients did not receive WBRT due to concerns regarding treatment and/or radioresistant histological tumor type. edema with mass effect on adjacent tissue. Approximately one half of the patients (45 patients) received corticosteroids before SRS. Ten patients (12%) required an increased dose of corticosteroids for the transient progression of neurological symptoms, presumably due to radiation-induced swelling of irradiated tissue within 72 hours of SRS.
Two patients underwent surgery at 6 to 7 months after SRS because of worsening neurological symptoms and neuroimaging-documented tumor progression. One patient presented with two melanoma metastases, one in the right parietal lobe measuring 2.0 cm in diameter and the other in the left posterior frontal lobe measuring 2.5 cm. Both of these lesions were treated with a MPD of 1600 cGy to the 83% IDS. The left posterior frontal lesion developed symptomatic and neuroimaging-documented progression at 5.5 months after SRS. This male patient underwent surgical debulking, which revealed persistent tumor, and he died of leptomeningeal carcinomatosis shortly after treatment. The other patient with small cell lung carcinoma harbored three metastatic lesions in the brain. One lesion treated with 1750 cGy prescribed to 50% of IDS progressed 7 months after SRS, and the patient underwent surgical debulking at which time radiation-induced necrosis was revealed. The patient died of systemic progression at 5 months after surgery.
Four patients (5%) developed radiation-induced necrosis; one patient underwent surgery as described in the previous paragraph, and three other patients developed areas in the brain that were clinically suspicious for necrosis that were not proven pathologically.
DISCUSSION
In this study, 38 patients included in our analysis underwent SRS as a salvage therapy for tumor recurrence after WBRT. One could question the validity of grouping these patients in our analysis with the other 45 patients in whom SRS was performed for newly diagnosed tumors. On the one hand, in patients treated with SRS for recurrent tumor shorter survival should be expected, because some of their survival time has elapsed between the diagnosis of metastases, the point at which survival time is calculated, and the time of recurrence. On the other hand, longer survival could be expected in patients with recurrent tumors because of possible selection bias in favor of selecting biologically less aggressive tumors during the interval between initial treatment and recurrence. This concept was suggested in a study in which the authors found that a significant prognostic factor predicting longer survival was an interval of more than 1 year between the treatment of intracranial metastases to recurrence as compared with an interval of less than 1 year. 5 Both expectations of survival length in patients with recurrent tumors could be true, depending on patient characteristics. For this reason, we analyzed the outcomes between the two groups (recurrent and newly diagnosed) and found that the survival lengths were comparable (Table 4) . This finding is similar to that reported in other
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Radiosurgery for multiple brain metastases studies, 1, 13, 18 which indicates comparable outcomes in patients treated with newly diagnosed disease and those treated with recurrent disease. Because of the comparable outcome in our two groups, we thought it justified to combine them to increase the sample size and to assess the affect of SRS on overall survival and the prognostic factors that may help predict which patients will most likely benefit from SRS.
Patterns of Failure and LPFS and RPFS
The authors of several retrospective studies have indicated that SRS achieves local control of intracranial disease in 80 to 95% of patients with metastases. 1, 2, 12, 14, 15, [17] [18] [19] It is almost certain that local control with SRS is better than that for historical controls treated with WBRT alone, although no randomized study has ever been performed. Presently, there is an ongoing Radiation Therapy Oncology Group study in which WBRT is being compared with combined WBRT/SRS in patients with one to three unresected metastases. Results of our previous studies 9,10 have indicated a LPFS rate of approximately 80% at 2 years after SRS in patients with brain metastases, and in the present study a very similar LPFS rate was shown.
Regional progression of intracranial disease was a more common pattern of failure than local progression after SRS. In our previous study, 9 multiple metastases were associated with a higher risk of regional progression. The actuarial risk of regional progression was 81% in patients with multiple metastases (19% of RPFS) and 34% in patients with a single metastasis at 2 years (66% of RPFS), which was statistically significant (p = 0.03, log-rank test). A similar observation was reported by Kihlstrom, et al., 15 who treated brain metastases mainly with SRS without WBRT and demonstrated that, following SRS, new metastases in the brain were observed in 13% of patients with a single metastasis, 34% of those with two or three metastases, and 100% of those with four or five metastases. In the present study we included only patients in whom multiple metastases were demonstrated at the time of SRS, and the RPFS rate was 48% at 1 year and 18% at 2 years (Fig. 1) . The majority of patients (82% at 2 years) eventually developed new metastases in the brain, and this was a major cause of neurological-related death (Fig. 3) . If regional progression was the major contributor to neurological-related death, it is reasonable to determine the role of WBRT in conjunction with SRS to eradicate occult micrometastases in the brain. It is hard to draw any conclusions regarding the role of WBRT in conjunction with SRS from retrospective data reported in the literature, and it is sometimes rather confusing because the definition of local (or regional) control varies among authors. Nevertheless, a few retrospective studies including ours indicate that regional progression was more frequent in patients undergoing SRS alone than in those being treated with combined SRS/WBRT, although this did not result in an improvement of survival. 9, 13, 24 In contrast, Kihlstrom, et al., 15 found that in a subset of patients with a single metastasis, an 87% rate of intracranial tumor control was revealed following SRS without WBRT, and they concluded that elective WBRT is of no apparent value in this setting. In our subset analysis, median RPFS was longer in patients treated with combined SRS/WBRT than for those undergoing SRS alone (12 and 6 months, respectively), but the difference was not statistically significant (p = 0.36). There was no survival difference between these two groups ( Table 4 ). The role of WBRT in conjunction with SRS, however, could not be addressed in our retrospective analysis in which the treatment administered (SRS alone or combined SRS/WBRT) was dictated by the previous treatment history and tumor status (recurrent or newly diagnosed). The majority of patients with newly diagnosed brain metastases were treated with SRS in conjunction with WBRT, and in the majority of in patients who underwent SRS alone recurrent disease was revealed after previous WBRT. A fair comparison was not possible in this study because of the disparity between patient characteristics in these two treatment groups. The role of WBRT when combined with SRS requires further investigation, and its efficacy can only be determined by a prospective randomized study in which SRS is compared with combined SRS/WBRT among prognostically comparable patients.
Survival Length
Median survival after WBRT is 3 to 4 months. 3, [6] [7] [8] 11, 20, 21, 25 Although most patients die of systemic disease progression, being able to control intracranial disease is important because almost half of patients die of intracranial progression within a few months after WBRT. 3, 7, 8, 16, 21 Control of intracranial disease seems particularly important in patients with stable or minimal systemic disease. Tumor resection has been advocated in patients with a single metastasis to improve local control and prolong survival. 23 In two randomized trials the benefit of resection for single metastases has been confirmed. 21, 25 Survival length after SRS (with or without WBRT) is comparable with survival after tumor resection (combined with WBRT) for a single metastasis. In studies in which SRS is performed to treat patients with a single brain metastasis, 2,9,10,12 median survival ranged from 10 to 13 months, which was similar to survival after tumor resection. 21, 25 However, the role of SRS in patients with multiple brain metastases is controversial. In our previous study 9 we demonstrated that the number of metastases within the brain was a significant prognostic indicator for survival. In general, the fewer the number of metastases, the better the prognosis. The maximum number of metastases that may benefit from SRS has not been determined because of compounding prognostic factors such as KPS score and systemic disease status, which also affect survival. In our analysis of the prognostic variables that predicted survival, a KPS score greater than or equal to 70, the absence of extracranial disease, and fewer metastases had a favorable impact on survival length, and this finding has been confirmed by other reports in the literature. 4, 22 From our arbitrary division of the patients into several groups based on three important variables that predicted survival (number of metastases, KPS score and status of extracranial disease), we defined the favorable group that should have prolonged survival following SRS. In those patients with up to 3 metastatic lesions and a KPS score greater than or equal to 70, regardless of extracranial disease status, the median survival was 7 months or longer (Table 5 ). However, patients with four or more metastases were less likely to benefit from SRS; in this group of patients the median survival was 2.7 months following SRS. However, in the subgroup analysis of patients with four or more metastases, those patients with no evidence of extracranial disease (controlled primary disease and no evidence of systemic disease) lived longer (median survival 7.4 months) than the remaining patients (Table 5 ). These patients may potentially benefit from SRS, and they should be carefully evaluated to rule out the presence of systemic disease before treatment.
CONCLUSIONS
An absence of extracranial disease, a KPS score greater than or equal to 70, and fewer number of metastases were significant predictors of prolonged survival in patients with multiple metastases. Stereotactic radiosurgery appears to be a reasonable treatment option in patients with up to three metastatic lesions when their KPS score is greater than or equal to 70, regardless of extracranial disease status. In patients with four or more metastases, SRS should be reserved for those with no extracranial disease.
